Scientists Behind Trial of Replimmune’s Tumor Destroyer Protest FDA’s Rejection

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined in the complete response letter for the melanoma candidate RP1.